Literature DB >> 16196281

In vitro anti-tumor immune response induced by dendritic cells transfected with recombinant adenovirus carrying mutant K-ras genes.

Feng Zhao1, Qinghua Zhou, Yanrong Lu, Yang Qin, Jie Zhang, Jinsong Li, Jianjun Wang.   

Abstract

The specific anti-tumor immune response induced by mouse bone marrow dendritic cells (DCs) transfected with recombinant adenovirus carrying mutant k-ras genes was investigated. DCs were generated from mouse bone marrow in the presence of rmGM-CSF (3.3 ng/mL) and rmIL-4 (1.3 ng/mL) and detected by FACS, and then transfected with the recombinant adenovirus encoding mutant k-ras gene. The efficacy of transfection and T cell stimulating activity of DCs were detected. CTL activity of the mice vaccinated with DCs was observed. The results showed that DCs had dendritic veiled morphology. BmDCs highly expressed B7-1 (80%), B7-2 (77%), MHC II (70%), CD11c (65%), CD40 (70%) and CD54 (96%) with FACS, and no significant difference in the expression was observed before and after the transfection (P > 0.05). The DCs transfected by mutant k-ras gene could significantly stimulate lymphocytes proliferation as compared with those transfected by Ad-c or non-modified DCs (P < 0.05). DC vaccine transfected by mutant k-ras gene could induce CTL activity against Lewis lung cancer, but not against B16. The specific cytotoxicity against Lewis lung cancer in Ad-k-ras/12-transduced DC group was significantly higher than those in the control, vector and non-transfected DCs groups (P < 0.05). It was concluded that special antitumor response could be induced by DCs transfected with recombinant adenovirus carrying mutant k-ras genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16196281     DOI: 10.1007/bf02828201

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  13 in total

1.  Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells.

Authors:  L Zhong; A Granelli-Piperno; Y Choi; R M Steinman
Journal:  Eur J Immunol       Date:  1999-03       Impact factor: 5.532

2.  [Construction of mutant k-ras gene recombinant adenovirus].

Authors:  Feng Zhao; Qinghua Zhou; Yang Qin; Zhiling Sun; Zefang Sun
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2002-02-20

3.  A simplified system for generating recombinant adenoviruses.

Authors:  T C He; S Zhou; L T da Costa; J Yu; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 4.  K-ras p21 expression and activity in lung and lung tumors.

Authors:  G Ramakrishna; G Sithanandam; R Y Cheng; L W Fornwald; G T Smith; B A Diwan; L M Anderson
Journal:  Exp Lung Res       Date:  2000-12       Impact factor: 2.459

5.  Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.

Authors:  E S Bergmann-Leitner; J A Kantor; W L Shupert; J Schlom; S I Abrams
Journal:  Cell Immunol       Date:  1998-08-01       Impact factor: 4.868

6.  Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant.

Authors:  R E Hunger; C U Brand; M Streit; J A Eriksen; M K Gjertsen; I Saeterdal; L R Braathen; G Gaudernack
Journal:  Exp Dermatol       Date:  2001-06       Impact factor: 3.960

Review 7.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

8.  A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion.

Authors:  Boris Linard; Stéphane Bézieau; Houssem Benlalam; Nathalie Labarrière; Yannick Guilloux; Elisabeth Diez; Francine Jotereau
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

9.  Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.

Authors:  S I Abrams; M J Dobrzanski; D T Wells; S F Stanziale; S Zaremba; L Masuelli; J A Kantor; J Schlom; L ] Masuelle L [corrected to Masuelli
Journal:  Eur J Immunol       Date:  1995-09       Impact factor: 5.532

10.  Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.

Authors:  S I Abrams; S F Stanziale; S D Lunin; S Zaremba; J Schlom
Journal:  Eur J Immunol       Date:  1996-02       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.